Bioventix (BVXP) AI Stock Analysis

• Market Cap: £123.71M
• Dividend Yield: 6.54%
• Average Volume (3M): 8.49K
• Price to Earnings (P/E): 15.8
• Beta (1Y): -0.19
• Revenue Growth: 6.17%
• EPS Growth: -3.43%
• Country: UK
• Employees: 17
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): 1.50
• Shares Outstanding: 5,219,656
• 10 Day Avg. Volume: 14,635
• 30 Day Avg. Volume: 8,491
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 19.92
• Price to Cash Flow (P/CF): 17.50
• P/FCF Ratio: 17.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Bioventix exhibits strong financial health with commendable profitability and a robust balance sheet, which are significant strengths. Although the stock is currently under technical pressure, its fair valuation and attractive dividend yield provide a positive investment case. Corporate events indicate promising future growth, contributing to an overall favorable outlook.

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

How the Company Makes Money

Bioventix makes money by licensing its proprietary antibodies to global diagnostics companies that incorporate them into their own diagnostic testing systems. The company generates revenue through upfront fees, milestone payments, and royalties based on the sales of diagnostic products that utilize its antibodies. These revenue streams are bolstered by long-term relationships with major diagnostics companies and continuous development of novel antibodies to meet emerging market needs. Bioventix's focus on high-quality, niche antibody products helps secure a competitive position and steady demand within the diagnostics industry.

Bioventix Financial Statement Overview

Summary

Overall, Bioventix is in a strong financial position with commendable profitability, a debt-free balance sheet, and robust cash flow management. The company exhibits consistent growth and stability, positioning it well within the biotechnology industry. Potential risks are minimal due to the absence of debt, though maintaining growth momentum will be crucial.

Income Statement

Bioventix demonstrates strong profitability with impressive gross and net profit margins. The company has shown consistent revenue growth over the years, with a notable increase of 6.17% from 2023 to 2024. Additionally, EBIT and EBITDA margins are robust, indicating effective operational management.

Balance Sheet

The balance sheet of Bioventix is exceptionally strong, characterized by a zero-debt position which eliminates financial leverage risks. The company has a high equity ratio, reflecting solid financial stability. Return on Equity remains impressive, showcasing efficient utilization of equity to generate profits.

Cash Flow

Bioventix displays healthy cash flow management with consistent free cash flow generation and a solid operating cash flow to net income ratio. The free cash flow has shown growth and remains well-aligned with net income, highlighting efficient cash conversion.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
13.61M	12.82M	11.72M	10.93M	10.31M
	Gross Profit
12.57M	11.86M	10.87M	9.98M	9.36M
	EBIT
10.60M	10.04M	9.16M	8.35M	7.96M
	EBITDA
10.74M	10.20M	9.32M	8.22M	8.11M
	Net Income Common Stockholders
8.10M	8.37M	7.67M	6.73M	7.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.00M	5.72M	6.13M	6.49M	8.08M
	Total Assets
13.73M	13.28M	13.12M	12.91M	13.30M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-6.00M	-5.72M	-6.13M	-6.49M	-8.08M
	Total Liabilities
1.73M	1.22M	1.30M	1.09M	778.87K
	Stockholders Equity
12.00M	12.06M	11.82M	11.82M	12.52M
Cash Flow		Free Cash Flow
8.53M	7.89M	7.55M	6.11M	7.38M
	Operating Cash Flow
8.55M	7.90M	7.56M	6.37M	7.72M
	Investing Cash Flow
-15.91K	-10.58K	-11.76K	-259.83K	-561.28K
	Financing Cash Flow
-8.25M	-8.30M	-7.92M	-7.69M	-5.62M

Bioventix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2425.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Negative. The current price of 2425 is below the 20-day moving average (MA) of 2677.00, below the 50-day MA of 2857.30, and below the 200-day MA of 3576.24, indicating a bearish trend. The MACD of -87.98 indicates Positive momentum. The RSI at 27.32 is Positive, neither overbought nor oversold. The STOCH value of 43.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BVXP.

Bioventix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	79 Outperform	£123.71M	15.77	69.08%	6.54%	6.17%	-3.43%
CML	67 Neutral	£35.01M	27.43	2.61%	5.00%	17.36%	-71.37%
HSD	62 Neutral	£63.96M	39.74	8.08%	9.57%	35.39%	-76.12%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
SYN	38 Underperform	£3.19M	0.50	56.96%	―	-55.66%	―

Bioventix Corporate Events

Bioventix Reports Steady Revenue with Promising Future Prospects

Bioventix reported a 1% increase in revenue to £6.73 million for the six months ending December 2024, though profit before tax fell by 4% due to increased R&D spending. Despite steady sales in core antibodies, including vitamin D and troponin, the company is optimistic about future growth driven by increased sales of Tau antibodies for Alzheimer’s disease testing and ongoing research in industrial pollution and water quality projects. The interim dividend rose by 3% to 70p per share, reflecting the company’s commitment to shareholder returns. Bioventix anticipates a return to growth in 2026 as new applications for their antibodies gain traction, particularly in neurological blood testing and industrial applications.